Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Ozempic (semaglutide) is an injectable medication initially designed to manage type 2 diabetes. Over the past few years, its potential to aid weight loss has captured more public attention.

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

People taking semaglutide drugs like Ozempic typically expect to lose excess weight — not hair. But that’s precisely what happened to Desiree Rodriguez, who has been sharing her journey on ...

The FBI says counterfeit versions of the drugs can cause health issues. The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide ...

Semaglutide medications like Ozempic and Wegovy have exploded in popularity in recent years due to their effectiveness in diabetes control and weight loss. Research has revealed additional ...

Patients who received preoperative semaglutide had lower postoperative total weight loss at 12 months compared with controls. Median HbA1c levels and diabetes remission at 1 year were similar ...

Semaglutide medications like Ozempic and Wegovy have exploded in popularity in recent years due to their effectiveness in diabetes control and weight loss. Research has revealed additional ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease. ️ The ...

Studies show promising results for semaglutide as a potential treatment for alcohol use disorder. Semaglutide, a GLP-1 drug, was initially used for type 2 diabetes treatment and weight loss.

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...